Show simple item record

2017-06-28Zeitschriftenartikel DOI: 10.1080/14737167.2017.1343145
A systematic review of the health economic consequences of quadrivalent influenza vaccination
dc.contributor.authorBoer, Pieter T. de
dc.contributor.authorMaanen, Britt M. van
dc.contributor.authorDamm, Oliver
dc.contributor.authorUltsch, Bernhard
dc.contributor.authorDolk, Franklin C.K.
dc.contributor.authorCrépey, Pascal
dc.contributor.authorPitman, Richard
dc.contributor.authorWilschut, Jan C.
dc.contributor.authorPostma, Maarten J.
dc.date.accessioned2018-05-07T20:19:42Z
dc.date.available2018-05-07T20:19:42Z
dc.date.created2017-08-01
dc.date.issued2017-06-28none
dc.identifier.otherhttp://edoc.rki.de/oa/articles/reqQeRkwNSA/PDF/21gpm1EJCmZfw.pdf
dc.identifier.urihttp://edoc.rki.de/176904/2739
dc.description.abstractBackground: Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should overcome a potential reduced vaccine protection due to mismatches between TIV and circulating B viruses. In this study, we systematically reviewed the available literature on health economic evaluations of switching from TIV to QIV. Areas covered: The databases of Medline and Embase were searched systematically to identify health economic evaluations of QIV versus TIV published before September 2016.A total of sixteen studies were included, thirteen cost-effectiveness analyses and three cost-comparisons. Expert commentary: Published evidence on the cost-effectiveness of QIV suggests that switching from TIV to QIV would be a valuable intervention from both the public health and economic viewpoint. However, more research seems mandatory. Our main recommendations for future research include: 1) more extensive use of dynamic models in order to estimate the full impact of QIV on influenza transmission including indirect effects, 2) improved availability of data on disease outcomes and costs related to influenza type B viruses, and 3) more research on immunogenicity of natural influenza infection and vaccination, with emphasis on cross-reactivity between different influenza B viruses and duration of protection.eng
dc.language.isoeng
dc.publisherRobert Koch-Institut, Infektionsepidemiologie
dc.subjectinfluenzaeng
dc.subjectvaccinationeng
dc.subjectvaccineeng
dc.subjectEconomic evaluationeng
dc.subjectcost-effectivenesseng
dc.subjectquadrivalenteng
dc.subjectmodeleng
dc.subject.ddc610 Medizin
dc.titleA systematic review of the health economic consequences of quadrivalent influenza vaccination
dc.typeperiodicalPart
dc.identifier.urnurn:nbn:de:0257-10054039
dc.identifier.doi10.1080/14737167.2017.1343145
dc.identifier.doihttp://dx.doi.org/10.25646/2664
local.edoc.container-titleExpert Review of Pharmacoeconomics & Outcomes Research
local.edoc.fp-subtypeArtikel
local.edoc.type-nameZeitschriftenartikel
local.edoc.container-typeperiodical
local.edoc.container-type-nameZeitschrift
local.edoc.container-urlhttp://www.tandfonline.com/doi/full/10.1080/14737167.2017.1343145
local.edoc.container-publisher-nameTaylor & Francis Group
local.edoc.container-volume17
local.edoc.container-issue3
local.edoc.container-year2017

Show simple item record